Form 4: Cytokinetics CEO Robert Blum Reports Stock Sale to Cover Restricted Stock Unit Vesting
SEC Form 4
Cytokinetics CEO Robert Blum sold shares of common stock on March 17, 2025, to cover taxes associated with the vesting of restricted stock units.
Summary
- Robert I Blum, President & CEO of Cytokinetics Inc, reported a transaction on March 17, 2025.
- Blum sold 12,648 shares of Common Stock at a price of $44.38.
- This sale was to cover transaction in connection with the vesting of restricted stock units.
- Following the transaction, Blum directly owns 326,533 shares of Common Stock.
- Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. This transaction is a common practice to cover tax obligations related to vesting equity.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of transaction: Sale of Common Stock and signature date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.